WSTAM
EBS icon

Wilbanks Smith & Thomas Asset Management’s Emergent Biosolutions EBS Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-23
Closed -$2K – 600
2018
Q3 		$2K Buy
+23
New +$1.34K ﹤0.01% 1390

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's EBS Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Emergent Biosolutions (EBS) in Q4 2018, closing a stake of 23 shares — an estimated $2K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in EBS in Q3 2018 and held it in 1 quarter. The position peaked at $2K in Q3 2018. 297 funds tracked by Wall St. Rank hold EBS as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Emergent Biosolutions position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 23 Emergent Biosolutions shares in Q4 2018, an estimated $2K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Emergent Biosolutions in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Emergent Biosolutions position peaked at $2K in Q3 2018.
  • 297 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.